Clinical Trial Update: Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating whether aromatase inhibitors promote weight loss in severely obese men with hypogonadotropic hypogonadism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadotropic Hypogonadism
• Obesity

Drugs mentioned

• Aromatase inhibitors (aromatase inhibitor)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Hypogonadism, Hypogonadotropic, Obesity | Phase 4 | Status: COMPLETED